Algernon Pharmaceuticals Inc. (AGNPF) Research
Algernon Pharmaceuticals Inc. is a biopharmaceutical firm actively engaged in drug development at the clinical trial stage. Its therapeutic endeavors span a range of challenging medical conditions, including non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), persistent cough, and acute lung damage linked to COVID-19, with operations primarily in Canada and Australia. Their flagship investigational drug, NP-120, functions as an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and concurrently acts as an agonist for the Sigma-1 receptor, a crucial chaperone protein whose expression is heightened during endoplasmic reticulum stress. Additionally, Algernon is advancing AP-188, a psychedelic agent from the tryptamine class, for treating ischemic stroke in human patients. To support its stroke clinical research program for AP-188, the company has established a collaboration with Charles River Laboratories for preclinical investigations. Established in 2015, the firm maintains its principal office in Vancouver, Canada.
Market snapshot
- Symbol
- AGNPF
- Price
- $0.25
- Day change
- -29.27%
- Market cap
- $157.5K
- P/E ratio
- -0.08x
- 52-week range
- 0.23-0.64
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 1 month
Recent news
- Algernon Health announces effective date of name change to Grey Health Matters
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) told investors that its previously announced rebranding to Grey Matters Health will take effect April 21,...
- Algernon Health to rebrand as Grey Matters Health, sharpen focus on Alzheimer's diagnostics
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) said on Wednesday it plans to change its corporate name to Grey Matters Health Inc, reflecting a strategic shift toward brain health and the growing Alzheimer's disease diagnostics market. The company has reserved the new ticker symbol ‘GREY' with the Canadian Securities Exchange and said updated symbols for its US and Frankfurt listings will be announced later.
- Algernon Health CEO outlines US brain imaging network plans - ICYMI
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) earlier this week outlined plans to expand into nuclear medicine with the launch of a network of...
Peer companies
Open Algernon Pharmaceuticals Inc. (AGNPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.